Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects aged 35 to 50 years old~* Subjects with the intention to undergo facial aesthetic treatment and who are likely to benefit from a combination of injection treatments and the benefit can be shown by improvements in their global facial aesthetic appearance and satisfaction.~* Subjects with nasolabial folds assessed as mild or moderate.~* Subjects with upper facial lines to be treated (at least two of glabellar lines, crow´s feet and/or forehead lines) assessed as moderate or severe, when the severity of the lines has an important psychological impact on the subject.~* Subjects with signed informed consent.~Exclusion Criteria:~* Obvious facial sagging (major loss of facial fat/volume).~* Signs or symptoms of eyelid ptosis or signs of compensatory frontalis muscle activity.~* Heavily scarred or sun-damaged facial skin.~* Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster/herpes simplex near or on the areas to be treated.~* Cancerous or pre-cancerous lesions in the areas to be treated.~* Facial tissue augmenting therapy or revitalization treatment with hyaluronic acid (HA) or collagen, or botulinum toxin treatment during the last 12 months.~* Procedures or treatments inducing an active dermal response such as laser, Intense Pulsed Light, chemical peeling, microdermabrasion, retinoids within the last 6 months.~* Any aesthetic surgery of the face.~* Permanent implant or aesthetic treatment with non-HA or non-collagen products in the face.~* History of severe keloids and/or hypertrophic scars.~* Neuromuscular junctional disorders (e.g. myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis) or history of dysphagia and aspiration.~* Known hypersensitivity to hyaluronic acid, botulinum toxin, lidocaine hydrochloride or other amide-type anesthetics.~* History of autoimmune diseases.~* Any medical condition that in the opinion of the investigator would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may affect the general condition or may require frequent medical treatment).~* Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs \[NSAIDs\]), Omega-3 or vitamin E within 10 days before study treatment, or a history of bleeding disorders.~* Immunosuppressive therapy, chemotherapy, or systemic corticosteroids within the last 3 months prior to baseline visit.~* Female subjects who are pregnant or plan to become pregnant within the study timeframe, or who are nursing.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Azzalure/Dysport as single treatment (Type: EXPERIMENTAL): Azzalure/Dysport as single treatment at initial treatment
- Filler as single treatment (Type: EXPERIMENTAL): Filler as single treatment at initial treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete